GoAI
Get started
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc.

INO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.18

−$0.03 · -2.48%

Aug 21, 4:00 PM ET

Pre-market

$1.18

$0.00 · 0.00%

Aug 24, 8:26 AM ET

INO company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

20

Overpriced

Momentum

28

Weakening

Sentiment

65

Bullish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jacqueline E. Shea
Listed since
Dec 8, 1998
Employees
112

Market position

Day range

Current $1.18

52-week range

Current $1.18

Open
$1.24
Previous close
$1.21
Volume
5.02M
1.52× average
Average volume
3.29M
Average daily volume
Market cap
81.53M USD
Beta
1.51
Market reference 1
50-day average
$1.0356
+13.94% above average
200-day average
$1.4697
-19.71% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
46.68M USD
P/E (TTM)
-1.01×
P/B (TTM)
22.03×
P/S (TTM)
0×
EV / EBITDA
-0.57×
Earnings yield
-104.12%
Free cash flow yield
-108.99%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-352.53%
Return on assets
-114.31%
Return on invested capital
-259.45%

Financial health

Debt / equity
1.83×
Current ratio
1.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends13397%-39791%-92980%-146168%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -16972.34%Operating margin, FY2022: -2607.35%Operating margin, FY2023: -17300.28%Operating margin, FY2024: -51616.91%Operating margin, FY2025: -132871.32%Net margin, FY2021: -17109.87%Net margin, FY2022: -2726.67%Net margin, FY2023: -16239.87%Net margin, FY2024: -49254.27%Net margin, FY2025: -130000.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -16972.34%. Operating margin FY2022 -2607.35%. Operating margin FY2023 -17300.28%. Operating margin FY2024 -51616.91%. Operating margin FY2025 -132871.32%. Net margin FY2021 -17109.87%. Net margin FY2022 -2726.67%. Net margin FY2023 -16239.87%. Net margin FY2024 -49254.27%. Net margin FY2025 -130000.00%.

Income trends

Revenue

65.34K USD-69.99%

Operating income

−86.82M USD+22.76%

Net income

−84.95M USD+20.80%
Income trends across reported periods41.65M USD−83.91M USD−209.48M USD−335.05M USDRevenue, FY2021: 1.77M USDRevenue, FY2022: 10.26M USDRevenue, FY2023: 832.01K USDRevenue, FY2024: 217.76K USDRevenue, FY2025: 65.34K USDOperating income, FY2021: −301.22M USDOperating income, FY2022: −267.57M USDOperating income, FY2023: −143.94M USDOperating income, FY2024: −112.4M USDOperating income, FY2025: −86.82M USDNet income, FY2021: −303.66M USDNet income, FY2022: −279.82M USDNet income, FY2023: −135.12M USDNet income, FY2024: −107.25M USDNet income, FY2025: −84.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.77M USD. Revenue FY2022 10.26M USD. Revenue FY2023 832.01K USD. Revenue FY2024 217.76K USD. Revenue FY2025 65.34K USD. Operating income FY2021 −301.22M USD. Operating income FY2022 −267.57M USD. Operating income FY2023 −143.94M USD. Operating income FY2024 −112.4M USD. Operating income FY2025 −86.82M USD. Net income FY2021 −303.66M USD. Net income FY2022 −279.82M USD. Net income FY2023 −135.12M USD. Net income FY2024 −107.25M USD. Net income FY2025 −84.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue65.34K USD217.76K USD832.01K USD10.26M USD1.77M USD
Gross profit65.34K USD217.76K USD832.01K USD10.26M USD1.77M USD
Research and development54.21M USD75.62M USD86.68M USD187.65M USD249.24M USD
Selling, general, and administrative32.68M USD37M USD47.58M USD90.19M USD53.75M USD
Operating expenses86.89M USD112.62M USD144.77M USD277.84M USD302.99M USD
Interest income2.42M USD4.77M USD8.13M USD4.78M USD3.36M USD
Interest expense—177.83K USD1.22M USD1.25M USD1.94M USD
Depreciation and amortization2.99M USD3.13M USD3.5M USD5.5M USD4.73M USD
Operating income−86.82M USD−112.4M USD−143.94M USD−267.57M USD−301.22M USD
Net income−84.95M USD−107.25M USD−135.12M USD−279.82M USD−303.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+15.04%
11 comparable reports
Latest EPS result
-0.07
Estimate -0.22 · Beat by 67.69%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.13-0.23-0.58-0.94Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -0.69, estimate -0.87, surprise +20.69%, Beat. Q2 2025, reported May 13, 2025: actual -0.51, estimate -0.74, surprise +31.08%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.61, estimate -0.63, surprise +3.17%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.87, estimate -0.422, surprise -106.32%, Miss. Q1 2026, reported Mar 12, 2026: actual 0.06, estimate -0.37, surprise +116.22%, Beat. Q2 2026, reported May 13, 2026: actual -0.28, estimate -0.35, surprise +20.00%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.07, estimate -0.217, surprise +67.69%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate -0.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.45M1.64M822.24K8.5KQ1 '25BeatQ2 '25BeatQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual 116.99K USD, estimate 50K USD, surprise +133.99%, Beat. Q2 2025, reported May 13, 2025: actual 65.34K USD, estimate 10K USD, surprise +553.43%, Beat. Q3 2025, reported Aug 12, 2025: actual —, estimate 10K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual —, estimate 10K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 12, 2026: actual —, estimate 333.33K USD, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual —, estimate 333.33K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual —, estimate 533.33K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 10, 2026: actual —, estimate 2.27M USD, surprise —, Comparison unavailable.

INO news

marketbeat.com

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for…

Read source
seekingalpha.com

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Read source
prnewswire.com

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act…

Read source
zacks.com

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Read source
prnewswire.com

INOVIO to Report Second Quarter Financial Results on August 12, 2026

PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases,…

Read source
gurufocus.com

INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Announces Pricing of $20.0 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa., July 29, 2026

Read source

INO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.76M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
652.17K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
343.43K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
103.29K
Weight
0.45%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research INO

research.disclaimer